Novavax (NVAX) Debt Ratio (2010 - 2026)
Novavax's (NVAX) quarterly Debt Ratio came in at 0.28 in Q1 2026, up 34.41% quarter-over-quarter from 0.21 in Q4 2025.
Novavax (NVAX) Debt Ratio (2010 - 2026) Analysis & Trends
Novavax's Debt Ratio history runs 8 years deep, the most recent figure standing at 0.28 for Q1 2026.
- On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.28 in Q1 2026; TTM through Mar 2026 was 0.28, a N/A change from a year earlier, with the FY2025 full-year figure at 0.21, changed N/A from the prior year.
- Debt Ratio advanced to 0.28 in Q1 2026 per NVAX's latest filing, from 0.21 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.28 in Q1 2026 and bottomed at 0.21 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | 0.28 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.28 |
| Dec 31, 2025 | 0.21 |
| Sep 30, 2015 | 0.00 |
| Jun 30, 2015 | 0.00 |
| Mar 31, 2015 | 0.00 |
| Dec 31, 2014 | 0.00 |
| Mar 31, 2014 | 0.00 |
| Dec 31, 2013 | 0.00 |
| Sep 30, 2013 | 0.01 |
| Jun 30, 2013 | 0.02 |
| Mar 31, 2013 | 0.01 |
| Dec 31, 2012 | 0.01 |
| Sep 30, 2012 | 0.01 |
| Jun 30, 2012 | 0.01 |
| Mar 31, 2012 | 0.01 |
| Dec 31, 2011 | 0.00 |
| Sep 30, 2011 | 0.00 |
| Jun 30, 2011 | 0.00 |
| Dec 31, 2010 | 0.00 |